Product Description
LT-300 Device For Treating Dry Advanced Macular Degeneration Granted CE Mark; light delivery system (Sourced from: https://www.lumithera.com/lumithera-lt-300-device-for-treating-dry-advanced-macular-degeneration-granted-ce-mark/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: LumiThera
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02725762 |
LIGHTSITE1 | N/A |
Completed |
Macular Degeneration |
2018-07-01 |
2021-02-19 |
Primary Endpoints|Treatments |